Which company does neratinib/neratinib come from?

Neratinib/Neratinib is an oral, irreversible inhibitor of human epidermal growth factor receptor HER1 (EGFR), HER2 and HER4. The drug was originally developed by Pfizer and is currently developed by Puma Biotechnology, Inc. It is mainly used to treat HER2-positive (HER+) breast cancer. Neratinib contains the active drug neratinib, which belongs to the kinase inhibitor class of drugs. Neratinib kills cancer cells by permanently attaching to their receptors (docking stations). By attaching to these receptors, neratinib stops cancer cells from growing. This causes cancer cells to die.

Neratinib is used to treat adults with early-stage HER2-positive (HER2+) breast cancer who have previously taken trastuzumab. WithHER2+ cancer, the cancer cells have abnormally high levels of a protein called HER2. For this reason, neratinib is used as adjuvant therapy (a treatment used to prevent the cancer from coming back). Neratinib is also used to treat advanced or metastatic HER2+ breast cancer (that has spread to other parts of the body) in adults who have tried two or more other HER2 breast cancer treatments. For this purpose, neratinib is taken with capecitabine. Diarrhea is a common adverse reaction of neratinib, as it is with other tyrosine kinase inhibitors, but it can be effectively controlled by preventing diarrhea and/or adjusting the drug dose.

In summary, Puma Biotechnology, as the current developer and manufacturer of neratinib/neratinib, provides a new treatment option for patients with HER2-positive breast cancer. If it is determined that neratinib is safe and effective for the patient, it can be taken for a long time under the guidance of a doctor.